Janssen Research & Development, LLC: Phase 3 study in Prostatic Neoplasms (400 participants)
Janssen Research & Development, LLC: Phase 3 study in Prostatic Neoplasms (400 participants). Its enrollment of 400 is above the median of 80 (87th percentile). Dated 5 days ago, it is inside the fresh trigger window. Score 90/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 400 · 87th percentile of 8,879 ClinicalTrialStartPulse records · 5.0x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer |
| NCT ID | NCT07906717 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Prostatic Neoplasms |
| Intervention types | drug |
| Target enrollment | 400 |
| Site countries | United States, Israel |
| Posted | 2026-10-30 |
| Planned start | 2026-10-29 |
| Event | Newly registered study |
| Event date | 2026-10-30 |
| enrollment percentile | 87th of 8,879 (median 80, 5.0x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Janssen Research & Development, LLC
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of US records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Janssen Research & Development + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-30
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Cancer Institute (NCI) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Janssen Research & Development, LLC and 2,512 US peers
- US ClinicalTrialStartPulse records like this one: 2,512
- Janssen Research & Development, LLC's enrollment: 87th percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every US peer: $502,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
90 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 400 participants planned.
What is the ClinicalTrialStartPulse record for Janssen Research & Development, LLC?
Janssen Research & Development, LLC registered a Phase 3 study (NCT07906717) in Prostatic Neoplasms targeting 400 participants, posted 2026-10-30.
How does Janssen Research & Development, LLC compare to other ClinicalTrialStartPulse records?
Its enrollment of 400 sits in the upper half (87th percentile) of 8,879 records; the median is 80. It is fresh: dated 5 days ago, inside the window where early outreach matters most. Its Score of 90/100 puts it among the stronger signals in this feed.
Janssen Research & Development, LLC vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Janssen Research & Development, LLC | US | 400 | 87th | 2026-10-30 |
| Janssen-Cilag Ltd. | US | 288 | 82nd | 2026-11-03 |
| Genmab | US | 600 | 91st | 2026-11-03 |
| Genmab | US | 191 | 75th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor Janssen Research & Development, LLC and peer phase 3 records
Get new ClinicalTrialStartPulse records like Janssen Research & Development, LLC by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.